Applications of minimal physiologically-based pharmacokinetic models
暂无分享,去创建一个
[1] S. Kety. The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.
[2] E. M. Renkin. Effects of blood flow on diffusion kinetics in isolated, perfused hindlegs of cats; a double circulation hypothesis. , 1955, The American journal of physiology.
[3] E. M. Renkin. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. , 1959, The American journal of physiology.
[4] C. Crone,et al. THE PERMEABILITY OF CAPILLARIES IN VARIOUS ORGANS AS DETERMINED BY USE OF THE 'INDICATOR DIFFUSION' METHOD. , 1963, Acta physiologica Scandinavica.
[5] M. Rowland,et al. Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. , 1968, Journal of pharmaceutical sciences.
[6] K. Bischoff,et al. Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.
[7] A. Goldstein,et al. The Fundamental Concepts of Pharmacology. (Book Reviews: Principles of Drug Action. The Basis of Pharmacology) , 1970 .
[8] M. Barza,et al. SOME DETERMINANTS OF THE DISTRIBUTION OF PENICILLINS AND CEPHALOSPORINS IN THE BODY. PRACTICAL AND THEORETICAL CONSIDERATIONS * , 1974, Annals of the New York Academy of Sciences.
[9] A. Karim. The pharmacokinetics of Norpace. , 1975, Angiology.
[10] M. Barza,et al. Comparative Pharmacokinetics of Cefamandole, Cephapirin, and Cephalothin in Healthy Subjects and Effect of Repeated Dosing , 1976, Antimicrobial Agents and Chemotherapy.
[11] W. Jusko,et al. Pharmacokinetics of methicillin in patients with cystic fibrosis. , 1977, The Journal of infectious diseases.
[12] E. M. Renkin. Multiple pathways of capillary permeability. , 1977, Circulation research.
[13] D. Spyker,et al. Pharmacokinetics of Amoxicillin: Dosage Nomogram for Patients with Impaired Renal Function , 1979, Antimicrobial Agents and Chemotherapy.
[14] M. Pfeffer,et al. Comparative Pharmacokinetics of Ceforanide (BL-S786R) and Cefazolin in Laboratory Animals and Humans , 1980, Antimicrobial Agents and Chemotherapy.
[15] S. Barriere,et al. Pharmacokinetics of mecillinam in health subjects , 1980, Antimicrobial Agents and Chemotherapy.
[16] B. Meyers,et al. Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics , 1980, Antimicrobial Agents and Chemotherapy.
[17] P. Welling,et al. Mezlocillin Pharmacokinetics After Single Intravenous Doses to Patients with Varying Degrees of Renal Function , 1980, Antimicrobial Agents and Chemotherapy.
[18] R. Wise,et al. The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. , 1980, The Journal of infectious diseases.
[19] D. Kampf,et al. Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency , 1981, Antimicrobial Agents and Chemotherapy.
[20] W J Jusko,et al. Prednisolone metabolism and excretion in the isolated perfused rat kidney. , 1981, Drug metabolism and disposition: the biological fate of chemicals.
[21] W. Jusko,et al. Distribution volume related to body weight and protein binding. , 1982, Journal of pharmaceutical sciences.
[22] E. S. Waller,et al. The Effect of Probenecid on Nafcillin Disposition , 1982, Journal of clinical pharmacology.
[23] P Heizmann,et al. Pharmacokinetics and bioavailability of midazolam in man. , 1983, British journal of clinical pharmacology.
[24] M. Pfeffer,et al. Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine , 1983, Antimicrobial Agents and Chemotherapy.
[25] P. McNamara,et al. Fraction unbound in interstitial fluid. , 1983, Journal of pharmaceutical sciences.
[26] R. Blouin,et al. Clinical Pharmacokinetics of Verapamil , 1984, Clinical pharmacokinetics.
[27] M. Eichelbaum,et al. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. , 1984, British journal of clinical pharmacology.
[28] Griaznova Ns,et al. [Penicillin-binding proteins. Their enzymatic activity and properties]. , 1986 .
[29] B. Winblad,et al. Single-dose pharmacokinetics of dicloxacillin in healthy subjects of young and old age. , 1986, Scandinavian journal of infectious diseases.
[30] M. Dudley,et al. Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans , 1986, Antimicrobial Agents and Chemotherapy.
[31] L. A. Beightol,et al. Comparative pharmacokinetics of azlocillin and piperacillin in normal adults , 1986, Antimicrobial Agents and Chemotherapy.
[32] O. Cars. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[33] C A Shanks,et al. Minimal compartmental model of circulatory mixing of indocyanine green. , 1992, The American journal of physiology.
[34] B. Gunter,et al. Effects of a TV Drama Series upon Public Impressions about Psychiatrists , 1994, Psychological reports.
[35] M. Avram,et al. A recirculatory pharmacokinetic model describing the circulatory mixing, tissue distribution and elimination of antipyrine in dogs. , 1994, The Journal of pharmacology and experimental therapeutics.
[36] B. Haraldsson,et al. Transport of macromolecules across microvascular walls: the two-pore theory. , 1994, Physiological reviews.
[37] R K Jain,et al. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.
[38] P. du Souich,et al. Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers. , 2003, British journal of clinical pharmacology.
[39] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[40] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[41] L. Lidgren,et al. Pharmacokinetics of cloxacillin in patients undergoing hip or knee replacement , 1997, European Journal of Clinical Pharmacology.
[42] R. Junghans. Finally! the Brambell receptor (FcRB) , 1997, Immunologic research.
[43] D. Greenblatt,et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.
[44] I. Tamai,et al. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. , 1999, Journal of pharmaceutical sciences.
[45] C. Kohlsdorfer,et al. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. , 1999, The Journal of antimicrobial chemotherapy.
[46] Michael P. Jones,et al. Gender‐Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in Humans , 2000, Journal of clinical pharmacology.
[47] G Benoni,et al. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. , 2001, Journal of pharmaceutical sciences.
[48] J. Ghuysen. Penicillin‐Binding Proteins , 2002 .
[49] E. Schuetz,et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.
[50] J. Valentin. Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.
[51] D. Levitt,et al. The pharmacokinetics of the interstitial space in humans , 2003, BMC clinical pharmacology.
[52] W. Jusko,et al. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. , 2003, Journal of pharmaceutical sciences.
[53] M. Roberts,et al. The effects of posture on the pharmacokinetics of intramuscular benzylpenicillin , 2004, European Journal of Clinical Pharmacology.
[54] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[55] M. Weiss. Modelling of initial distribution of drugs following intravenous bolus injection , 2004, European Journal of Clinical Pharmacology.
[56] P. Vicini,et al. Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors , 2004, Clinical Cancer Research.
[57] M. Roberts,et al. The effect of posture on the pharmacokinetics of intravenous benzylpenicillin , 2004, European Journal of Clinical Pharmacology.
[58] Malcolm Rowland,et al. Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of pharmacokinetics and biopharmaceutics.
[59] F. Rowell,et al. Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites , 2004, European Journal of Clinical Pharmacology.
[60] W. L. Chiou. Potential pitfalls in the conventional pharmacokinetic studies: Effects of the initial mixing of drug in blood and the pulmonary first-pass elimination , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[61] A. Atkinson,et al. Analysis of the contributions of permeability and flow to intercompartmental clearance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[62] Malcolm Rowland,et al. Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[63] Harold Boxenbaum,et al. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics , 1982, Journal of Pharmacokinetics and Biopharmaceutics.
[64] D. P. Vaughan,et al. Applications of a recirculatory stochastic pharmacokinetic model: Limitations of compartmental models , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[65] P. Parren,et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. , 2006, Cancer research.
[66] K Rowland-Yeo,et al. Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[67] U. Holzgrabe,et al. Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers , 2007, Antimicrobial Agents and Chemotherapy.
[68] Joseph P. Balthasar,et al. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[69] Y. Tsukamoto,et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. , 2007, British journal of clinical pharmacology.
[70] U. Holzgrabe,et al. Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin , 2007, Antimicrobial Agents and Chemotherapy.
[71] S. Cox. Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis. , 2007, Journal of veterinary pharmacology and therapeutics.
[72] N. Lehn,et al. Tissue concentrations of vancomycin and Moxifloxacin in periprosthetic infection in rats , 2007, Acta orthopaedica.
[73] L. Giot,et al. A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. , 2008, International journal of clinical pharmacology and therapeutics.
[74] J. Widness,et al. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin. , 2008, The Journal of pharmacy and pharmacology.
[75] J. Hoffman. Practical and Theoretical Considerations , 2009 .
[76] W. White,et al. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. , 2009, Clinical therapeutics.
[77] Yuichi Sugiyama,et al. Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development , 2009, The AAPS Journal.
[78] Y. Nasuhara,et al. Comparison of the Pharmacodynamics of Biapenem in Bronchial Epithelial Lining Fluid in Healthy Volunteers Given Half-Hour and Three-Hour Intravenous Infusions , 2009, Antimicrobial Agents and Chemotherapy.
[79] Feng Li,et al. Cell culture processes for monoclonal antibody production , 2010, mAbs.
[80] Wilhelm Huisinga,et al. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[81] W. Busse,et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.
[82] H. Wakelee,et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[83] Jianghua Chen,et al. Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts , 2010, mAbs.
[84] Yuichi Sugiyama,et al. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[85] K. Fujiwara,et al. Immunocytochemistry for Amoxicillin and Its Use for Studying Uptake of the Drug in the Intestine, Liver, and Kidney of Rats , 2010, Antimicrobial Agents and Chemotherapy.
[86] Daniel A. Beard,et al. Development of appropriate equations for physiologically based pharmacokinetic modeling of permeability-limited and flow-limited transport , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[87] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[88] D. Choi,et al. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[89] John C. Davis,et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial , 2012, Arthritis Research & Therapy.
[90] S. Haddad,et al. In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. , 2012, Journal of pharmaceutical sciences.
[91] H. Lode,et al. Pharmacokinetics of Temocillin in Volunteers , 2012, Drugs.
[92] W. Huisinga,et al. Modeling Interindividual Variability in Physiologically Based Pharmacokinetics and Its Link to Mechanistic Covariate Modeling , 2012, CPT: pharmacometrics & systems pharmacology.
[93] Qingpu Wang,et al. Comparison of c-Nd:YVO4/YVO4 raman lasers and c-Nd:YVO4 self-Raman lasers , 2012 .
[94] H. Lennernäs,et al. The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. , 2012, Molecular pharmaceutics.